These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 26382309)

  • 21. Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms.
    Speroff L; Whitcomb RW; Kempfert NJ; Boyd RA; Paulissen JB; Rowan JP
    Obstet Gynecol; 1996 Oct; 88(4 Pt 1):587-92. PubMed ID: 8841224
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estradiol/progesterone (Bijuva) for menopausal vasomotor symptoms.
    Med Lett Drugs Ther; 2019 Jul; 61(1575):99-101. PubMed ID: 31381541
    [No Abstract]   [Full Text] [Related]  

  • 23. Effect of an estradiol gel with monthly or quarterly progestogen on menopausal symptoms and bleeding.
    Hirvonen E; Crona N; Wahlström T; Bäckström AC
    Climacteric; 2000 Dec; 3(4):262-70. PubMed ID: 11910586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postmenopausal women.
    Archer DF; Schmelter T; Schaefers M; Gerlinger C; Gude K
    Menopause; 2014 Mar; 21(3):227-35. PubMed ID: 23963307
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estradiol gel 0.1% relieves vasomotor symptoms independent of age, ovarian status, or uterine status.
    Hedrick RE; Ackerman RT; Koltun WD; Halvorsen MB
    Menopause; 2010; 17(6):1167-73. PubMed ID: 20720511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vasomotor hot flushes and 24-hour ambulatory blood pressure in normotensive women: A placebo-controlled trial on post-menopausal hormone therapy.
    Tuomikoski P; Haapalahti P; Sarna S; Ylikorkala O; Mikkola TS
    Ann Med; 2010 Jul; 42(5):334-43. PubMed ID: 20429800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Micro-dose transdermal estradiol for relief of hot flushes in postmenopausal Asian women: a randomized controlled trial.
    Haines C; Yu SL; Hiemeyer F; Schaefers M
    Climacteric; 2009 Oct; 12(5):419-26. PubMed ID: 19479489
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review.
    Nelson HD
    JAMA; 2004 Apr; 291(13):1610-20. PubMed ID: 15069049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of a seven-day, transdermal estradiol drug-delivery system: comparison with conjugated estrogens and placebo. The Transdermal Estradiol Patch Study Group.
    Gordon SF; Thompson KA; Ruoff GE; Imig JR; Lane PJ; Schwenker CE
    Int J Fertil Menopausal Stud; 1995; 40(3):126-34. PubMed ID: 7663539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vasomotor symptoms resulting from natural menopause: a systematic review and network meta-analysis of treatment effects from the National Institute for Health and Care Excellence guideline on menopause.
    Sarri G; Pedder H; Dias S; Guo Y; Lumsden MA
    BJOG; 2017 Sep; 124(10):1514-1523. PubMed ID: 28276200
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: a double-blind, randomized, placebo-controlled, multicenter study.
    Lee BS; Kang BM; Yoon BK; Choi H; Park HM; Kim JG
    Maturitas; 2007 Aug; 57(4):361-9. PubMed ID: 17467203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vasomotor hot flashes and heart rate variability: a placebo-controlled trial of postmenopausal hormone therapy.
    Lantto H; Haapalahti P; Tuomikoski P; Viitasalo M; Väänänen H; Sovijärvi AR; Ylikorkala O; Mikkola TS
    Menopause; 2012 Jan; 19(1):82-8. PubMed ID: 21934534
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gabapentin vs. low-dose transdermal estradiol for treating post-menopausal women with moderate to very severe hot flushes.
    Aguirre W; Chedraui P; Mendoza J; Ruilova I
    Gynecol Endocrinol; 2010 May; 26(5):333-7. PubMed ID: 20050764
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms.
    Bouchard P; Panay N; de Villiers TJ; Vincendon P; Bao W; Cheng RJ; Constantine G
    Climacteric; 2012 Feb; 15(1):12-20. PubMed ID: 22066790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study.
    Santoro N; Allshouse A; Neal-Perry G; Pal L; Lobo RA; Naftolin F; Black DM; Brinton EA; Budoff MJ; Cedars MI; Dowling NM; Dunn M; Gleason CE; Hodis HN; Isaac B; Magnani M; Manson JE; Miller VM; Taylor HS; Wharton W; Wolff E; Zepeda V; Harman SM
    Menopause; 2017 Mar; 24(3):238-246. PubMed ID: 27779568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study.
    Swanson SG; Drosman S; Helmond FA; Stathopoulos VM
    Menopause; 2006; 13(6):917-25. PubMed ID: 17006377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microdose transdermal estrogen therapy for relief of vulvovaginal symptoms in postmenopausal women.
    Bachmann GA; Schaefers M; Uddin A; Utian WH
    Menopause; 2009; 16(5):877-82. PubMed ID: 19458560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial.
    Speroff L; Gass M; Constantine G; Olivier S;
    Obstet Gynecol; 2008 Jan; 111(1):77-87. PubMed ID: 18165395
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and tolerability of pulsed estrogen therapy: a 12-week double-blind placebo-controlled study in highly symptomatic postmenopausal women.
    Rozenbaum H; Chevallier O; Moyal M; Durand G; Perineau M; This P;
    Climacteric; 2002 Sep; 5(3):249-58. PubMed ID: 12419083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause.
    Archer DF; Seidman L; Constantine GD; Pickar JH; Olivier S
    Am J Obstet Gynecol; 2009 Feb; 200(2):172.e1-10. PubMed ID: 19110224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.